Skip to main content
OpenTrials

Clinical trial condition

Marginal Zone Lymphoma

Explore clinical trials studying Marginal Zone Lymphoma. Study availability and eligibility vary by location and protocol.

114 public trials 41 recruiting studies
Refine in advanced search Browse all conditions

Marginal Zone Lymphoma trial results

Completed

Open-Label, Multi-Center, Two-Part, Ph1 Study to Characterize the PKs of an Intravenous Micro-Dose of [14C]-Tazemetostat (EPZ 6438) and the ADME of an Oral [14C]-Labeled Dose of Tazemetostat in Subjects With B-Cell Lymphomas or Adv Solid Tumors

NCT03010982

Conditions
Advanced Solid Tumors, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, +17 more
Locations
  • The Clatterbridge Cancer Centre NHS Foundation Trust Bebington, Wirral, United Kingdom
  • Royal Liverpool and Broadgreen University Hospital Trust Liverpool, United Kingdom
View Trial Details
Completed

Immune Responses to COVID-19 Vaccination in Lymphoma Patients

NCT04858568

Conditions
Burkitt Lymphoma, Chronic Disease, Chronic Lymphocytic Leukemia, +42 more
Locations
  • Bedfordshire Hospitals NHS Foundation Trust Bedford, Bedfordshire, United Kingdom
  • Portsmouth Hospitals University NHS Trust Portsmouth, Hampshire, United Kingdom
  • University Hospital Southampton NHS Foundation Trust Southampton, Hampshire, United Kingdom
  • Wye Valley NHS Trust Hereford, Herefordshire, United Kingdom
View Trial Details
Completed

A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)

NCT03833180

Conditions
Acute Lymphoid Leukemia, Acute Myeloid Leukemia, Blood Protein Disorders, +49 more
Locations
  • City of Hope ( Site 0010) Duarte, California, United States
  • University of California - San Diego ( Site 0003) La Jolla, California, United States
  • UCLA Hematology & Oncology ( Site 0007) Los Angeles, California, United States
  • University of Nebraska Medical Center ( Site 0006) Omaha, Nebraska, United States
View all 14 locations
View Trial Details
Completed

Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma

NCT01000753

Conditions
Adult Immunoblastic Lymphoma, Central Nervous System Non-Hodgkin Lymphoma, Childhood Immunoblastic Lymphoma, +35 more
Locations
  • Children's Hospital of Alabama Birmingham, Alabama, United States
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Phoenix Childrens Hospital Phoenix, Arizona, United States
  • Arkansas Children's Hospital Little Rock, Arkansas, United States
View all 130 locations
View Trial Details
Completed

Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients

NCT03028103

Conditions
Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Hemic and Lymphatic Diseases, +15 more
Locations
  • University of Arizona Cancer Center Tucson, Arizona, United States
  • Moffitt Cancer Center Tampa, Florida, United States
  • Columbia University Medical Center New York, United States
View Trial Details
Completed

Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin's Lymphoma

NCT03364231

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +19 more
Locations
  • TG Therapeutics Investigational Trial Site Washington D.C., District of Columbia, United States
  • TG Therapeutics Investigational Trial Site Boston, Massachusetts, United States
  • TG Therapeutics Investigational Trial Site Hackensack, New Jersey, United States
  • TG Therapeutics Investigational Trial Site New York, United States
View Trial Details

Related conditions